More recently, Xu et al. [35] showed that mutated deficient CDKN2A in RCC patients is associated with sarcomatoid differentiation, tumor progression, poor prognosis and primary resistance to Sunitinib, and potential favorable responses to ICIs. The gene discussed is CDKN2A; the disease is renal cell carcinoma.